<?xml version='1.0' encoding='utf-8'?>
<document id="23873267"><sentence text="Triamcinolone and ritonavir leading to drug-induced Cushing syndrome and adrenal suppression: description of a new case and review of the literature."><entity charOffset="0-13" id="DDI-PubMed.23873267.s1.e0" text="Triamcinolone" /><entity charOffset="18-27" id="DDI-PubMed.23873267.s1.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.23873267.s1.e0" e2="DDI-PubMed.23873267.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23873267.s1.e0" e2="DDI-PubMed.23873267.s1.e1" /></sentence><sentence text="The protease inhibitor (PI) ritonavir is a potent inhibitor of cytochrome P450 (CYP) 3A4 activity and frequently prescribed to boost the effectiveness of other PIs as part of highly active antiretroviral therapy"><entity charOffset="28-37" id="DDI-PubMed.23873267.s2.e0" text="ritonavir" /></sentence><sentence text=" It is well established that ritonavir is capable of inducing iatrogenic Cushing syndrome (ICS) through a drug-drug interaction with inhaled fluticasone that leads to the inhibition of CYP3A activity"><entity charOffset="29-38" id="DDI-PubMed.23873267.s3.e0" text="ritonavir" /><entity charOffset="141-152" id="DDI-PubMed.23873267.s3.e1" text="fluticasone" /><pair ddi="false" e1="DDI-PubMed.23873267.s3.e0" e2="DDI-PubMed.23873267.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23873267.s3.e0" e2="DDI-PubMed.23873267.s3.e1" /></sentence><sentence text=" A rapidly increasing number of case reports are being published describing ICS induced by the interaction of ritonavir and injected corticosteroids, namely triamcinolone acetonide"><entity charOffset="110-119" id="DDI-PubMed.23873267.s4.e0" text="ritonavir" /><entity charOffset="133-148" id="DDI-PubMed.23873267.s4.e1" text="corticosteroids" /><entity charOffset="157-180" id="DDI-PubMed.23873267.s4.e2" text="triamcinolone acetonide" /><pair ddi="false" e1="DDI-PubMed.23873267.s4.e0" e2="DDI-PubMed.23873267.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23873267.s4.e0" e2="DDI-PubMed.23873267.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23873267.s4.e0" e2="DDI-PubMed.23873267.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23873267.s4.e1" e2="DDI-PubMed.23873267.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23873267.s4.e1" e2="DDI-PubMed.23873267.s4.e2" /></sentence><sentence text=" A review of the current literature identified 15 cases (including the one reported here) of ICS and suppression of the hypothalamic-pituitary-adrenal axis after periradicular injection of triamcinolone acetonide"><entity charOffset="189-212" id="DDI-PubMed.23873267.s5.e0" text="triamcinolone acetonide" /></sentence><sentence text=" Considering an aging human immunodeficiency virus (HIV)-infected population an increasing number of patients will present with degenerative musculoskeletal disease and be seeking pain relief" /><sentence text=" Based on data reported in the literature and our own experience triamcinolone injections during ritonavir-based therapy should be avoided"><entity charOffset="65-78" id="DDI-PubMed.23873267.s7.e0" text="triamcinolone" /><entity charOffset="97-106" id="DDI-PubMed.23873267.s7.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.23873267.s7.e0" e2="DDI-PubMed.23873267.s7.e0" /><pair ddi="false" e1="DDI-PubMed.23873267.s7.e0" e2="DDI-PubMed.23873267.s7.e1" /></sentence><sentence text=" After failure of all conservative therapeutic options methylprednisolone may represent a therapeutic alternative for steroid injections in HIV patients receiving PI-based antiviral therapy since it has to date not been associated with ICS"><entity charOffset="55-73" id="DDI-PubMed.23873267.s8.e0" text="methylprednisolone" /><entity charOffset="118-125" id="DDI-PubMed.23873267.s8.e1" text="steroid" /><pair ddi="false" e1="DDI-PubMed.23873267.s8.e0" e2="DDI-PubMed.23873267.s8.e0" /><pair ddi="false" e1="DDI-PubMed.23873267.s8.e0" e2="DDI-PubMed.23873267.s8.e1" /></sentence><sentence text=" " /></document>